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We report a case of long-term survival with complete remission after hepatic arterial infusion chemotherapy
(HAIC) for liver metastasis from gastric cancer. A 62-year-old man underwent radical distal gastrectomy with D2
lymphadenectomy for an advanced gastric cancer. Solitary liver metastasis in the S2/3 segment was detected
26 months after initial surgery. The patient underwent HAIC with systemic chemotherapy. Serum CEA levels rapidly
decreased, and CT scan showed disappearance of the tumor with complete clinical response 8 months after HAIC.
HAIC was performed 83 times in total, until the hepatic artery proper was adequately obstructed. No severe adverse
effects were observed during HAIC treatment. The patient is still disease-free without further chemotherapy more
than 12 years after HAIC. Our experience suggests that HAIC should be considered as a treatment option in
patients with resectable liver metastasis from gastric cancer. However, further studies are needed to verify the
validity of HAIC for resectable liver metastasis from gastric cancer.
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Gastric cancer is the fourth most common malignancy
worldwide [1]. Although the prognosis of gastric cancer
has significantly improved because of improvements in
disease diagnosis and treatment, the prognosis of recur-
rent gastric cancer remains poor [2]. Chemotherapy is
regarded as the standard treatment for recurrent gastric
cancer, although the median survival time of recurrent/
metastatic gastric cancer treated by chemotherapy is re-
portedly only 12.5–13.8 months [3–6], which seems to
be unsatisfactory. The liver is one of the most common
sites of recurrence of gastric cancer; however, the treat-
ment strategy for liver metastasis of gastric cancer has
not yet been established. Here, we report a case of
complete remission for more than 12 years following
hepatic arterial infusion chemotherapy (HAIC) in a pa-
tient with solitary metachronous liver metastasis from
gastric cancer. To the best of our knowledge, the present* Correspondence: t-toyokawa@med.osaka-cu.ac.jp
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tric cancer who was treated with HAIC without surgery.Case presentation
A 62-year-old man was referred to our institution in
February 2000, after being diagnosed with gastric cancer
as a result of medical examination for a 1-month history
of heart burn at another hospital. His family and clinical
histories were unremarkable. Laboratory data were within
normal limits. Serum carcinoembryonic antigen (CEA)
level was elevated to 185 ng/ml, but carbohydrate antigen
(CA) 19–9 was 33 U/ml, which was within the normal
range. Upper gastrointestinal endoscopy revealed a semi-
circumferential type 3 tumor primarily located at the
posterior wall of the gastric antrum. Histopathological
examination in our institution confirmed moderately differ-
entiated adenocarcinoma. Abdominal ultrasonography and
abdominal computed tomography (CT) revealed no suspi-
cious metastatic lesions in the liver, peritoneum, or lymph
nodes. Intraoperatively, we did not find tumor invasion to
adjacent organs, peritoneal dissemination, or liver metasta-
sis. On the basis of these findings, the patient underwentticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 2 Abdominal computed tomography revealing a 15 mm metastatic
lesion in the S2/3 segment of the liver (arrow)
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Billroth-I reconstruction in March 2000. The resected spe-
cimen showed a type 3 tumor that measured approximately
55 × 50 mm in size around the gastric antrum (Fig. 1).
Microscopic examination revealed a moderately differenti-
ated adenocarcinoma infiltrating the serosa, and the margin
was negative for cancer. The final pathological diagnosis of
the gastric cancer was T4aN3M0, Stage IIIC according to
the third English edition of the Japanese Classification of
Gastric Carcinoma [7]. His postoperative course was un-
eventful, and the patient was discharged on the 20th post-
operative day. The serum CEA level decreased to a normal
range within 3 months after surgery.
Following the operation, the patient started postopera-
tive adjuvant chemotherapy with uracil-tegafur (300 mg/
day; 100 mg three times daily after meals) from April
2000. However, about 15 months after the initial surgery,
CEA levels began to gradually increase. The anticancer
drug was changed to S-1, but he could only receive S-1
for 2 weeks due to appetite loss. CT scan performed in
May 2002 revealed a 15-mm-sized metastatic lesion in
the S2/3 segment of the liver, without any other suspi-
cious lesions in the lymph nodes or peritoneum (Fig. 2).
Angiography revealed staining suggestive of a tumor in
the lateral segment of the left lobe of the liver, consistent
with the results of the CT scan (Fig. 3). Diagnosing soli-
tary liver metastasis, systemic chemotherapy using oral
5-FU (150 mg/day; 50 mg three times daily after meals)
with HAIC (500 mg 5-FU for 2 h, weekly) from the
proper hepatic artery through the femoral artery via a
subcutaneously implanted port, was started in July 2002.
Just before starting HAIC, CEA levels had increased to
297 ng/ml. After HAIC, CEA levels decreased rapidly
and CT scan showed disappearance of the tumor with
atrophic change of the left lobe, with a complete clinicalFig. 1 The resected specimen showing a type 3 tumor around the
gastric antrum measuring approximately 55 × 50 mm in sizeresponse being obtained in March 2003 (8 months after
commencement of HAIC) (Fig. 4). In total, HAIC was per-
formed 83 times until April 2004, by which time the hep-
atic artery proper was obstructed. During HAIC treatment,
no severe adverse effects were observed. After the catheter
was removed, CEA levels reached the normal range in
December 2004 (29 months after commencement of
HAIC), and oral administration of 5-FU was completed
in February 2007. Since completion of all chemother-
apy, the patient has been following up periodically on
an outpatient basis and is still disease-free with no
further chemotherapy as of April 2015 (Fig. 5).
Conclusions
The liver is one of the common sites of recurrence after
curative surgery for gastric cancer. Among initial re-
currence sites after curative gastrectomy, the liver was
reported to account for 15.8–33.1 % of cases [8–10].Fig. 3 Angiography revealing the tumor stain in the lateral segment
of the left liver lobe (arrow), consistent with CT scan findings
Fig. 4 Abdominal computed tomography reveals that the tumor
disappeared with atrophic change of the left lobe, together with

























Fig. 5 Clinical course and treatment of the patient. (1) Uracil-tegafur; (2) Hep
tomography
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(78.1 %) with recurrence in the liver had no extrahepatic
metastases. Liver metastases is considered a systemic dis-
ease that is not an indication for surgery with a curative
intent, as the Japanese Gastric Cancer Treatment Guide-
lines state that chemotherapy is the treatment to be
primarily considered for recurrent gastric cancer [11]. It is
generally believed that chemotherapy cannot ultimately
lead to complete cure even if patients are considered to
have a complete response, and hence, the goal of chemo-
therapy is to prolong survival. In fact, although long-term
survival after surgical resection for liver metastasis has
been reported, few reports have documented long-term
survival after HAIC for liver metastasis. To the best of our
knowledge, this is the first report of a patient with long-
term survival who experienced complete remission for
more than 12 years following HAIC for liver metastasis
from gastric cancer.
Since reports of the efficacy of systemic chemother-
apies for gastric cancer [3, 4], the number of patients
undergoing HAIC has been decreasing. HAIC is one of
the effective local treatments for liver metastases and is
considered for patients who have no extrahepatic metas-
tasis and when the occurrence of hepatic metastasis is7/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3
atic arterial infusion chemotherapy; (3) Complete response; (4) Computed
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systemic chemotherapy, HAIC can provide high concen-
trations of anticancer agents directly to the liver, result-
ing in a decrease in adverse drug effects. The reported
response rates of HAIC are 71–83 % [12–14], which
seems to be higher than those with systemic chemother-
apy that have been reported in randomized controlled
trials [2]. However, there is currently no established regi-
men of HAIC. Ojima et al. [14] reported that low dose
5-FU (500 mg, weekly), which was also used in the
present case, could be used for a long period (the average
treatment period of HAIC was 14.7 months) without
severe adverse effects in 18 patients. Similarly, our patient
underwent HAIC for 21 months without suffering any
adverse effects. Since one of the disadvantages of HAIC is
its inability to control extrahepatic tumor growth, we
initially treated the patient with systemic chemotherapy.
Although the standard regimen of systemic chemotherapy
for metastatic gastric cancer in Japan was not yet estab-
lished at the time, we decided to use oral 5-FU because
the patient had not been able to tolerate S-1 due to a loss
of appetite.
While the efficacy of curative resection for liver metas-
tasis of colorectal cancer has been established [15], the
significance of liver resection for metastasis from gastric
cancer is still controversial. Although liver resection for
metastases from gastric cancer is expected to be a poten-
tially curative treatment, the results of some studies have
been disappointing, suggesting that this type of surgery
should be limited to certain patient subtypes as a part of
multimodal treatment [16, 17]. Okano et al. [18] reported
that solitary and metachronous metastases were independ-
ent favorable prognostic factors in patients who under-
went hepatectomy for liver metastasis from gastric cancer.
Others have also identified the same factors as inde-
pendent favorable prognostic factors of liver resection for
metastasis from gastric cancer [19–22]. Therefore, patients
with these factors could be considered as potentially good
candidates for curative liver resection. From this perspec-
tive, curative liver resection might have been indicated in
our patient; however, because CT scan showed complete
remission at the second follow-up examination after start-
ing HAIC, together with rapidly decreasing CEA levels, we
decided to continue HAIC, with which the complete re-
mission persisted for more than 10 years even after the
HAIC was interrupted. Similarly, Ojima et al. [14] reported
one case that survived for more than 5 years without any
signs of recurrence after treatment with HAIC. Although
extremely rare, our case indicates that HAIC can lead to
complete cure in selected patients with liver metastasis
from gastric cancer.
Recurrence in the remnant liver after liver resection is
observed most frequently within 2 years of the initial
therapy, and no report has demonstrated the benefit ofre-resection of the liver. These findings suggest that
occult intrahepatic metastases may already exist at the
time of the liver resection in most cases. Lambert et al.
[23] advocated “a test of time” as an approach that iden-
tifies patients who are not likely to be cured by hepatic
resection for liver metastases from colorectal cancer.
This approach makes it possible to avoid unnecessary
liver resections by reevaluating the development of intra-
hepatic or extrahepatic metastases 3–6 months later. In
our case, HAIC with systemic chemotherapy prior to
surgery led to complete remission, resulting in avoidance
of liver resection. Hence, the “test of time” approach for
resectable liver metastasis from gastric cancer may be a
reasonable strategy.
We described long-term survival with complete remis-
sion in a patient who underwent HAIC for liver metasta-
sis from gastric cancer. Our experience suggests that
HAIC should be considered as a treatment option in pa-
tients with resectable liver metastasis from gastric can-
cer. However, further studies are needed to clarify which
treatment, surgery, systemic chemotherapy, or HAIC is
the most beneficial for resectable liver metastasis from
gastric cancer.
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